In 2024, SK Biopharmaceuticals completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
SK Biopharmaceuticals has also provided a category-level breakdown for 5 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021-2019 |
|---|---|---|---|---|
Total Scope 1 | 414a | 433b | 425a | |
Total Scope 2 | ||||
Market-Based | 1,197a | 1,046a | 936a | |
Location-Based | N/A | 1,046b | 936b | |
Total Scope 3 | 9,168a | 11,882.495b | 6,547a | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 1.1094a | 1.5591b | 2.1757a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2024, the total operational greenhouse gas (GHG) emissions of SK Biopharmaceuticals amounted to 1,611 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2023, the total operational greenhouse gas (GHG) emissions of SK Biopharmaceuticals increased by 8.92%, suggesting that the company faced challenges in reducing its emissions from its core operations.ab
In 2024, the total Scope 1 emissions of SK Biopharmaceuticals were 414 metric tons of CO₂ equivalent (tCO₂e).a
Since 2021, SK Biopharmaceuticals's Scope 1 emissions have increased by 5.08%, reflecting a rising long-term trend in Scope 1 emissions over time.ab
Compared to the previous year (2023), SK Biopharmaceuticals's Scope 1 emissions decreased by 4.39%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.ab
In 2024, SK Biopharmaceuticals reported Scope 2 greenhouse gas (GHG) emissions of 1,197 tCO₂e using the market-based method.a
In 2024, SK Biopharmaceuticals reported its Scope 2 emissions using the market-based method.a
In 2024, SK Biopharmaceuticals reported 9,168 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2024 disclosure of SK Biopharmaceuticals includes a breakdown across 5 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2023, demonstrating consistent Scope 3 emissions reporting coverage year over year.a
In 2024, SK Biopharmaceuticals reported total Scope 3 emissions of 9,168 metric tons of CO₂ equivalent (tCO₂e).a
Approximately 100% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0% came from downstream activities like product use, distribution, and end-of-life treatment.a
Compared to the previous year (2023), SK Biopharmaceuticals's Scope 3 emissions decreased by 22.84%, highlighting the company's efforts to lower indirect emissions from its value chain.ab
In 2024, SK Biopharmaceuticals reported emissions for 5 out of the 15 Scope 3 categories defined by the GHG Protocol.a
This partial disclosure allows for some insight into the company's indirect impacts.
In 2024, the largest contributors to SK Biopharmaceuticals's Scope 3 emissions were:a
In 2024, SK Biopharmaceuticals reported Scope 1 greenhouse gas (GHG) emissions of 414 tCO₂e and total revenues of USD 373 millions. This translates into an emissions intensity of 1.11 tCO₂e per millions USD.a
In 2024, SK Biopharmaceuticals reported a Scope 1 emissions intensity of 1.11 tCO₂e per millions USD. Compared to the peer group median of 4.58, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a
In 2024, SK Biopharmaceuticals ranked 8 out of 23 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
SK Biopharmaceuticals is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a
In 2024, SK Biopharmaceuticals reported a total carbon footprint of 10,779 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 19.33% decrease compared to 2023, indicating progress in reducing its overall greenhouse gas output.ab
The largest contributor to SK Biopharmaceuticals's total carbon footprint was Scope 3 emissions, accounting for 85.05% of the company's total carbon footprint, followed by Scope 2 emissions at 11.1%.a